Miragen Therapeutics is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a focus on microRNAs and their role in diseases. Co.'s product candidates include: cobomarsen, which is for the treatment of patients with certain cancers that have elevated microRNA-155, including cutaneous T-cell lymphoma, and adult T-cell leukemia/lymphoma; remlarsen, which is for the potential treatment of patients with pathological fibrosis, including idiopathic pulmonary fibrosis; and MRG-110, which is for the treatment of heart failure, wound healing, and other ischemic disease. We show 20 historical shares outstanding datapoints in our coverage of MGEN's shares outstanding history.
Understanding the changing numbers of MGEN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like MGEN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching MGEN by allowing them to research MGEN shares outstanding history
as well as any other stock in our coverage universe. |
Free MGEN Email Alerts:
Video: Shares Outstanding Importance
